EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

Which state and compounding-standard changes need separate review?

Dose Diligence research deskSection 04 · Page 9 of 17Last updated 17 Nov 2026

California is a useful example of why a federal analysis is insufficient—not a proxy for all 50 states. Its replacement compounding regulations became effective October 1, 2025, an older but still material baseline. The Board’s FAQs were revised in January 2026. Approved regulations; Board FAQs. (pharmacy.ca.gov)

The FAQs explain that a clinically significant patient-specific difference must be verified and documented by the pharmacist. They also describe written qualification procedures for storage, shipping containers and transportation of temperature-sensitive sterile preparations. Request evidence addressing both clinical documentation and distribution—not merely a sterile-compounding licence. (pharmacy.ca.gov)

Do not confuse a bill with an effective requirement. California Senate Appropriations records show AB 1990, concerning advertising of certain compounded obesity/weight-management medicines, was held in committee on August 13, 2026. The record located does not establish an enacted compliance deadline. Official committee results. (sapro.senate.ca.gov)

Do not call USP <797> a new 2026 rule. USP identifies November 1, 2023 as the official date of the major revision and explains that enforcement rests with the applicable jurisdiction, which may use a different date. USP FAQ. (pages.usp.org)

For multi-state telehealth, maintain a separate prescriber-authorisation check. HHS advises verifying patient location and consent before appointments and describes state-specific licensing pathways. A pharmacy’s shipping coverage does not complete that clinical-authorisation review. HHS cross-state licensing guidance. (telehealth.hhs.gov)

Sources cited on this page

  1. pharmacy.ca.gov · Source 1 ↗https://www.pharmacy.ca.gov/laws_regs/approved_regs.shtml
  2. pharmacy.ca.gov · Source 2 ↗https://pharmacy.ca.gov/online/faqs.shtml
  3. sapro.senate.ca.gov · Source 3 ↗https://sapro.senate.ca.gov/system/files/2026-08/hearing_results-8-13-26-suspense.pdf
  4. sapro.senate.ca.gov · Source 4 ↗https://sapro.senate.ca.gov/system/files/2026-08/hearing_results-8-13-26-suspense.pdf?utm_source=openai
  5. pages.usp.org · Source 5 ↗https://pages.usp.org/rs/711-SXF-172/images/USP_HQS_797_FAQs_December2023_V6__002.pdf?version=0
  6. pages.usp.org · Source 6 ↗https://pages.usp.org/rs/711-SXF-172/images/USP_HQS_797_FAQs_December2023_V6__002.pdf?version=0&utm_source=openai
  7. telehealth.hhs.gov · Source 7 ↗https://telehealth.hhs.gov/licensure/licensing-across-state-lines
  8. telehealth.hhs.gov · Source 8 ↗https://telehealth.hhs.gov/licensure/licensing-across-state-lines?_cldee=L_nLiRQy8eWGhDEgAws9POkBL4J4h1Xy_WSCPJIWHj2kc4ZY6Thn87NaDdkH_ZsA&esid=7e20895b-df1c-ee11-8f6e-000d3a323f9b&recipientid=contact-7ac1903f1dc5ea11a812000d3a5a17e3-b0e959b0de4248a5a04dc8569144e143&utm_source=openai
Section sources →